Redirecting host preexisting influenza A virus immunity for cancer immunotherapy

Chaganty, Bharat Kumar Reddy; Qiu, Songbo; Yang, Lu; López-Berestein, Gabriel; Özpolat, Bülent; Fan, Zhen

doi:10.1007/s00262-021-03099-9

Cited by 3 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 22 , 23 Importantly, bystander cells are not exhausted as they remain ignorant of tumor cells, 24 as evidenced by low expression levels of checkpoint receptors such as PD-1, lymphocyte activating gene 3 (LAG-3) and CD39 (encoded by ENTPD1 ) in both preclinical and clinical contexts. 24 , 25 , 26 Therefore, bystander CD8 T cells in tumors can show functionality in response to cognate antigen stimulation, 27 , 28 and some studies suggest that activating bystander CD8 T cells within the TME improves antitumor responses, 29 , 30 , 31 indicating their therapeutic potential.…”

Section: Introductionmentioning

confidence: 99%

IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

Lee,

Choi,

Tae

et al. 2024

Cell Reports Medicine

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

Lee,

Choi,

Tae

et al. 2024

Cell Reports Medicine

View full text Add to dashboard Cite

“…This suggested that in uenza viruses could induce apoptosis in cultured tumor cells in vitro [13]. Another study also found that pre-existing in uenza-A immunity could be used for cancer immunotherapy by delivering in uenza-A-related peptides to targeted tumors [14]. However, the relationships between the IAV and cancers remain unclear compared to validated oncoviruses.…”

Section: Introductionmentioning

confidence: 99%

Multi-omics approach reveals influenza-A virus target genes associated genomic, clinical and immunological characteristics in cancers

Wang¹,

Liao²,

Peng³

et al. 2023

Preprint

View full text Add to dashboard Cite

Influenza A virus has been shown to be closely linked to diverse malignancies and may work as an oncovirus. However, the specific role of influenza A virus as well as its target genes in cancer initiation and progression remain unclear. Thus, in this study, a comprehensive evaluation of influenza A virus target genes (IATGs) was performed in thirty-three tumor types by using multi-omics data from The Cancer Genome Atlas (TCGA) and The Cancer Proteome Atlas (TCPA) databases. In the genomic landscape, a high frequency of genetic and epigenetic alterations in the IATGs were found and subsequently affected tumor progression. Moreover, transcriptome analysis revealed that the expression of IATGs was differentially expressed in diverse tumors and could be used to predict clinical survival in patients. In addition, IATGs were also closely associated with cancer-related signaling pathways as well as the immune microenvironment. Furthermore, the involvement of IATGs in the regulation of the resistance of anti-cancer drugs was uncovered. The transcript expression of six identified IATGs in kidney renal clear cell carcinoma (KIRC) was validated by qRT-PCR. In conclusion, this study revealed the genomic alterations and clinical features of IATGs, which may provide new hints for exploring the potential molecular mechanisms between tumors and the influenza A virus. This will also provide new clues for developing novel targeted therapeutic strategies such as viral immunotherapy, promoting the discovery of tumor-related viruses, and designing individualized treatment for tumor patients.

show abstract

Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?

Groeneveldt¹,

Ende²,

Montfoort³

2023

Cytokine & Growth Factor Reviews

View full text Add to dashboard Cite

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy

Cited by 3 publications

References 45 publications

IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy

Multi-omics approach reveals influenza-A virus target genes associated genomic, clinical and immunological characteristics in cancers

Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?

Contact Info

Product

Resources

About